Understanding MET Exon 14 Skipping
In Metastatic Non-Small Cell Lung Cancer
About NSCLC
Non-small cell lung cancer (NSCLC) is not just 1 disease, but many types of disease with specific genetic differences. Certain people may have noninherited gene mutations that can cause their cancer cells to grow and multiply.
About MET exon 14 skipping
Gene changes (mutations) have been linked to cancer growth in metastatic non-small cell lung cancer (mNSCLC)
Certain noninherited gene mutations can cause MET exon 14 skipping, which is an abnormal change in a gene that makes a protein called mesenchymal-epithelial transition (MET)
MET exon 14 skipping has been linked to cancer growth in mNSCLC
MET exon 14 skipping can be detected by an FDA-approved comprehensive biomarker test
For people with mNSCLC with MET exon 14 skipping, there is an option to take the first FDA-approved targeted therapy, TABRECTA
